Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

Benzinga Newsdesk www.benzinga.com Positive 59.8%

Neg 0% Neu 0% Pos 59.8%

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.